山东新华医疗器械股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 10 月 18 日(星期五) 上午 11:00-12:00 投资者可于 2024 年 10 月 11 日(星期五) 至 10 月 17 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 shinva@163. com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 证券代码：600587 证券简称：新华医疗 公告编号：临 2024-034 山东新华医疗器械股份有限公司（以下简称"公司"）已于 2024 年 8 月 30 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 10 月 18 日上午 11:00- 12:00 举行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2]. Core Insights - The company reported a revenue of 5.187 billion yuan for the first half of 2024, reflecting a year-over-year growth of 2.24%, and a net profit attributable to shareholders of 484 million yuan, up 5.57% year-over-year [2]. - The medical device business is under pressure, but profitability continues to improve, with a gross margin of 26.65% and a net profit margin of 9.60% for the first half of 2024 [2]. - The company is focusing on cost reduction and efficiency improvements, leading to a significant enhancement in profitability metrics [2]. Revenue and Profit Forecast - The company is projected to achieve total revenues of 10.802 billion yuan, 11.671 billion yuan, and 12.637 billion yuan for the years 2024, 2025, and 2026, respectively, with growth rates of 7.89%, 8.05%, and 8.27% [3][4]. - Net profit attributable to shareholders is expected to reach 783 million yuan, 940 million yuan, and 1.162 billion yuan for the same years, with growth rates of 19.72%, 20.08%, and 23.62% [3][4]. Financial Metrics - The report highlights a projected PE ratio of 12x for 2024, 10x for 2025, and 8x for 2026, indicating a favorable valuation compared to comparable companies in the medical device sector [3]. - The company’s gross margin is expected to improve gradually, reaching 28.82% by 2026 [4]. Business Segment Performance - The medical device segment generated revenue of 1.887 billion yuan in the first half of 2024, down 2.55% year-over-year, while the pharmaceutical equipment segment saw revenue of 1.092 billion yuan, up 4.38% year-over-year [2]. - The company is adapting to market conditions by focusing on consumables and small-scale sterilization products, which are expected to drive growth in the second half of the year [2].

证券代码：600587 证券简称：新华医疗 公告编号：临 2024-033 山东新华医疗器械股份有限公司 关于公司产品获得三类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于近 日收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情 况如下： 一、医疗器械注册证的具体情况 1、产品名称： X 射线计算机体层摄影设备 2、注册证编号：国械注准 20243061705 3、注册人名称：山东新华医疗器械股份有限公司 4、注册人住所：山东省淄博市高新技术产业开发区新华医疗科技园 5、生产地址：淄博高新区齐祥路 3588 号 6、结构及组成：该产品由扫描架、扫描床、控制台、电源柜和选配件组成， 其中扫描架包含高压发生器、X 射线管组件、探测器、准直器，控制台含主机和 显示器，选配件包括头部延长板和头托。 7、型号、规格：XHCT-16iM 8、适用范围：该产品用于常规临床 CT 检查，可为放射治疗计划提供图像数 据。 9、批准日期 ...

Investment Rating - The report maintains a "Recommended" investment rating for the company with a target price of 25 yuan, compared to the current price of 16.62 yuan [1]. Core Views - The medical device sector is experiencing temporary pressure, but the company has optimized its expense ratio, leading to an improvement in net profit margin [1]. - The company reported a revenue of 5.187 billion yuan (+2.24%) and a net profit of 484 million yuan (+5.57%) for the first half of 2024 [1]. - The decline in medical device revenue is attributed to compliance actions and delayed procurement needs from hospitals [1]. - The international contract amount for pharmaceutical equipment has seen rapid growth, with domestic revenue at 5.082 billion yuan (+2.20%) and overseas revenue at 105 million yuan (+4.15%) [1]. - The company's gross margin slightly decreased to 26.65%, with the medical device segment's gross margin increasing to 43.29% despite a revenue decline [1]. - The overall expense ratio has improved, with a sales expense ratio of 7.88% (-0.78 percentage points) and a management expense ratio of 3.81% (-0.90 percentage points) [1]. - The company expects a gradual recovery in bidding activities in the second half of the year, maintaining profit forecasts for 2024-2026 [1]. Financial Summary - For the first half of 2024, the company reported a gross margin of 26.65%, with the medical device segment's gross margin at 43.29% and the pharmaceutical equipment segment's gross margin at 27.12% [1]. - The projected net profit for 2024-2026 is 830 million yuan, 1.04 billion yuan, and 1.28 billion yuan, respectively, with year-on-year growth rates of 27.3%, 24.7%, and 23.5% [2]. - The earnings per share (EPS) are expected to be 1.37 yuan, 1.71 yuan, and 2.11 yuan for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (PE) ratios of 12, 10, and 8 [2].

Investment Rating - The report maintains a "Buy" rating for Xinhua Medical [1] Core Views - In H1 2024, Xinhua Medical achieved operating revenue of 5.187 billion yuan (+2.24%) and a net profit attributable to shareholders of 484 million yuan (+5.57%), with a net profit margin of 9.6% (+0.19 percentage points) [1] - The company faced a decline in bidding for infection control products due to slow policy implementation, but expects recovery in H2 2024 as equipment update policies take effect [2] - The internationalization of pharmaceutical equipment is progressing, with significant growth in international trade contracts [2] - Cost control measures have significantly improved, with a reduction in sales and management expenses [2] Summary by Sections Financial Performance - In H1 2024, the company reported a revenue of 5.187 billion yuan, with a net profit of 484 million yuan and a non-recurring net profit of 474 million yuan [1] - For Q2 2024, revenue was 2.658 billion yuan (+0.91%) and net profit was 273 million yuan (+4.21%) [1] - The medical device segment generated revenue of 1.887 billion yuan (-2.55%) with a gross margin of 43.29% (+2.28 percentage points) [2] - The pharmaceutical equipment segment achieved revenue of 1.092 billion yuan (+4.38%) [2] Market Strategy - The company is focusing on major hospitals in the infection control sector and has achieved record high revenue in infection control consumables [2] - Continuous product upgrades and improvements in traditional surgical instruments have helped maintain market leadership [2] Cost Management - Sales expenses decreased by 6.94% to 409 million yuan, while management expenses fell by 17.41% to 198 million yuan [2] - R&D expenses increased by 3.75% to 18.53 million yuan, with several new products recognized for innovation [2] Profit Forecast - The report forecasts net profits of 818 million yuan, 950 million yuan, and 1.174 billion yuan for 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 13, 11, and 9 times [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights the company's focus on "medical devices + pharmaceutical equipment," improving operational structure and enhancing overall gross profit margin [1] - The company is expected to benefit from national policies supporting medical equipment updates, with an anticipated revenue increase from these initiatives [1] - The company has shown a commitment to cost control and profit expansion, aligning with ongoing state-owned enterprise reforms [1] Financial Performance Summary - For the first half of 2024, the company achieved operating revenue of 5.187 billion yuan, a year-on-year increase of 2.24%, and a net profit attributable to shareholders of 484 million yuan, up 5.57% [1] - The second quarter of 2024 saw operating revenue of 2.658 billion yuan, an increase of 0.91%, with a net profit of 273 million yuan, reflecting a growth of 4.21% [1] - The company’s net profit excluding non-recurring items reached 265 million yuan, marking a significant increase of 16.19% [1] Future Projections - The company is projected to achieve operating revenues of 11 billion yuan, 12 billion yuan, and 13 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 9.5%, 9.2%, and 8.5% [2][3] - Net profit attributable to shareholders is expected to reach 831 million yuan, 1.053 billion yuan, and 1.267 billion yuan for the same years, with growth rates of 27.0%, 26.8%, and 20.2% respectively [2][3] - The report anticipates an increase in gross margin from 27.4% in 2023 to 31.0% by 2026 [5] Cost Management - The report notes a decrease in sales expenses by 6.94%, management expenses by 17.41%, and financial expenses by 13.00%, indicating effective cost control measures [1] - The company’s R&D expense ratio increased by 3.75%, reflecting a commitment to innovation while managing other costs effectively [1] Market Position and Strategy - The company is focusing on enhancing its core business in medical devices and pharmaceutical equipment, with a strategic emphasis on improving operational efficiency and risk management [1] - The report indicates that the company is well-positioned to capitalize on the growing demand for medical equipment due to government support and market trends [1]

1、产品名称：全自动糖化血红蛋白分析仪 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于近 日收到山东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体 情况如下： 一、医疗器械注册证的具体情况 山东新华医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 证券代码：600587 证券简称：新华医疗 公告编号：临 2024-032 2、注册证编号：鲁械注准 20242220826 3、注册人名称：山东新华医疗器械股份有限公司 4、注册人住所：山东省淄博市高新技术产业开发区新华医疗科技园 5、生产地址：淄博高新区齐祥路 3588 号 6、结构及组成：全自动糖化血红蛋白分析仪主要由进样系统、液相色谱分离 系统、比色检测与控制系统，显示打印系统，软件（软件类型：嵌入式，发布版 本：1.0）组成。 7、型号、规格：SGH-400。 8、适用范围：基于高效液相色谱法与新华医疗生产的糖化血红蛋白分析用洗 脱液（高效液相色谱法）和糖化血红蛋白溶血剂（高 ...

公司代码：600587 公司简称：新华医疗 山东新华医疗器械股份有限公司 2024 年半年度报告 二〇二四年八月三十日 新华医疗 2024 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人王玉全、主管会计工作负责人周娟娟及会计机构负责人（会计主管人员）姚海云 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性陈述存在不确定性，不构成公司对投资者的实 质承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实 ...

证券代码：600587 证券简称：新华医疗 编号：临 2024-025 山东新华医疗器械股份有限公司 第十一届监事会第十二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、 误导性陈述或者重大遗漏负连带责任。 一、监事会会议召开情况 山东新华医疗器械股份有限公司（以下简称公司）第十一届监事会第十二次 会议于 2024 年 8 月 16 日以通讯和书面方式发出通知，据此通知，会议于 2024 年 8 月 28 日在公司三楼会议室召开，应到监事 3 名，实到 3 名。会议由监事会 主席牟乐海先生召集和主持，符合《公司法》和《公司章程》规定。 二、监事会会议审议情况 （一）审议通过《公司 2024 年半年度报告全文及摘要》，并对公司 2024 年 半年度报告全文及摘要发表审核意见 公司监事会根据《证券法》、《公开发行证券的公司信息披露内容与格式准 则第 3 号—半年度报告的内容与格式（2021 年修订）》、《上海证券交易所股票上 市规则（2023 年 2 月修订）》、《上海证券交易所上市公司自律监管指南第 2 号— 业务办理》等与半年度报告编制有关的各项规定，对董事会编制的 2 ...

中信建投证券股份有限公司 关于山东新华医疗器械股份有限公司 非公开发行股票限售股解禁上市流通的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"、"保荐机构"） 作为山东新华医疗器械股份有限公司（以下简称"新华医疗"、"公司"）非公 开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交 易所股票上市规则》和《上海证券交易所上市公司自律监管指引第 11 号——持 续督导》等相关法律法规的要求，对新华医疗非公开发行股票限售股解禁上市流 通事项进行了审慎核查，具体核查情况及核查意见如下： 一、本次限售股上市类型 本次上市流通的限售股类型为非公开发行限售股。 二、本次解禁限售股的基本情况 非公开发行核准情况 2022 年 6 月 13 日，中国证券监督管理委员会出具《关于核准山东新华医疗 器械股份有限公司非公开发行股票的批复》（证监许可[2022]1223 号），核准公 司非公开发行不超过 121,928,427 股新股，发生转增股本等情形导致总股本发生 变化的，可相应调整本次发行数量；该批复自核准发行之日起 12 个月内有效。 股份登记及限售安排 本次发行新增股份已于 2023 年 2 ...